Values First Advisors Inc. Sells 1,252 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Values First Advisors Inc. lessened its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 19.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,070 shares of the company’s stock after selling 1,252 shares during the period. Values First Advisors Inc.’s holdings in Axsome Therapeutics were worth $429,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Strategic Financial Concepts LLC bought a new stake in Axsome Therapeutics during the 4th quarter worth approximately $2,599,000. Lion Street Advisors LLC grew its holdings in Axsome Therapeutics by 16.3% during the fourth quarter. Lion Street Advisors LLC now owns 9,599 shares of the company’s stock worth $812,000 after buying an additional 1,344 shares in the last quarter. Calamos Advisors LLC purchased a new stake in Axsome Therapeutics in the 4th quarter valued at $1,084,000. abrdn plc raised its position in Axsome Therapeutics by 553.3% in the 4th quarter. abrdn plc now owns 72,179 shares of the company’s stock valued at $6,107,000 after buying an additional 61,131 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Axsome Therapeutics by 11.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,276 shares of the company’s stock valued at $869,000 after acquiring an additional 1,044 shares in the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on AXSM shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $139.00 target price on shares of Axsome Therapeutics in a research note on Wednesday, January 29th. Bank of America increased their price objective on shares of Axsome Therapeutics from $143.00 to $167.00 and gave the company a “buy” rating in a research note on Tuesday. Truist Financial boosted their target price on Axsome Therapeutics from $180.00 to $190.00 and gave the stock a “buy” rating in a research note on Monday, February 3rd. Needham & Company LLC reaffirmed a “buy” rating and set a $133.00 price target on shares of Axsome Therapeutics in a research report on Monday. Finally, William Blair reiterated an “outperform” rating on shares of Axsome Therapeutics in a report on Friday, January 24th. One investment analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $147.13.

Axsome Therapeutics Price Performance

AXSM opened at $131.55 on Thursday. The firm has a 50-day moving average price of $96.55 and a 200-day moving average price of $92.67. Axsome Therapeutics, Inc. has a twelve month low of $64.11 and a twelve month high of $134.18. The company has a quick ratio of 2.37, a current ratio of 2.44 and a debt-to-equity ratio of 1.97. The company has a market capitalization of $6.37 billion, a price-to-earnings ratio of -20.15 and a beta of 1.05.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.38) by $0.04. The business had revenue of $104.76 million during the quarter, compared to analyst estimates of $98.71 million. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. During the same period in the previous year, the business earned ($1.32) EPS. Equities analysts expect that Axsome Therapeutics, Inc. will post -4.7 EPS for the current year.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.